U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C24H38O4
Molecular Weight 390.5561
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIETHYLHEXYL PHTHALATE

SMILES

CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC

InChI

InChIKey=BJQHLKABXJIVAM-UHFFFAOYSA-N
InChI=1S/C24H38O4/c1-5-9-13-19(7-3)17-27-23(25)21-15-11-12-16-22(21)24(26)28-18-20(8-4)14-10-6-2/h11-12,15-16,19-20H,5-10,13-14,17-18H2,1-4H3

HIDE SMILES / InChI

Description

Diethylhexyl phthalate (Di-2-ethylhexyl phthalate, DEHP), the most frequently occurring plasticiser in medical equipment manufactured from polymers of vinyl chloride, forms about 40% w/w of tubes and containers used for storing blood and for haemodialysis. The plasticiser leaches out into liquids with lipid contents, although it is very sparingly soluble in purely aqueous solutions. On infusion of 2-3 1 of stored blood, up to 200 mg DEHP may be transferred to the patient, while much higher quantities may be given during dialysis, which is moreover often repeated frequently over long periods. The acute toxicity of DEHP is very low (greater than 20 g/kg as LD50 in rats), and the ester is rapidly metabolised to products which are excreted in the urine and bile; chronic toxicity from the levels of dosage obtaining is thus very improbable. Carcenogenicity has never been demonstrable in animals, while teratological effects are of a very low order. The uses of DEHP fall into two major categories: polymer uses (e.g. consumer products such as footwear, shower curtains and toys, medical devices and commercial/industrial uses) and non-polymer uses (e.g. dielectric fluids, paints, adhesives and inks). Non-polymer uses represent less than 5% of the total DEHP used in the USA. Approximately 45% of total consumption of DEHP in the USA is for plasticizing various industrial and commercial products. Industrial and commercial uses of DEHP include resilient flooring, wall covering, roofing, aluminium foil coating/laminating, paper coating, extrudable moulds and profiles, electronic component parts, and wire and cable coating and jacketing. Medical devices comprise approximately 25% of total manufacturing use of DEHP in the USA. Medical devices that contain DEHP include PVC sheet materials such as intravenous bags, and tubing used in a variety of medical applications.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct

PubMed

Sample Use Guides

In Vivo Use Guide
In vivo treatment regimens were: (i) female rats, 12 000 p.p.m. Diethylhexyl phthalate (DEHP) in the diet for 30 days; (ii) female rats, 12 000 p.p.m. in the diet for 30 days, followed by 500 mg/kg DEHP by gavage 2 h before sacrifice; (iii) male rats, 500 mg/kg DEHP by gavage 2, 12, 24, or 48 h before sacrifice; and (iv) male rats, 150 mg/kg/day by gavage for 14 days.
Route of Administration: Oral
In Vitro Use Guide
In vitro conditions were 0.1, 1.0 and 10.0 mM Diethylhexyl phthalate (DEHP) in the human hepatocyte cultures for 18 h. Primary cultures of human hepatocytes were prepared from freshly discarded surgical material and exposed to the same concentration of DEHP.